Corin aims high with implants for young active patients
This article was originally published in Clinica
Executive Summary
UK orthopaedic company Corin has filed for a listing on the London Stock Exchange and plans to raise around £22 million ($32 million). The company has developed reconstructive implants aimed at patients suffering from degenerative arthritis, with a particular emphasis on the younger patient.